Study of sleep–hormone timing after chemotherapy-related missed periods
Part of Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how the body’s daily timing (circadian rhythms) may affect ovarian function and fertility after chemotherapy. It includes women who stopped having periods after chemotherapy and may help explain what to expect for post-cancer fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman whose periods stopped after chemotherapy (chemotherapy-induced amenorrhea)
- Be age 25 to 35 when you would start the study
- Have received this specific chemotherapy plan: FEC 100 for 3 cycles plus docetaxel for 3 cycles
- Be willing to participate in the study and follow study procedures
- Have no other (different) chemotherapy treatment history than the one listed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at long-term ovarian (egg-producing) fertility after chemotherapy for lymphoma, about 5 years after treatment ends. It may help doctors better understand pregnancy potential and guide future family-planning care.
This study tests whether the timing of chemotherapy during your menstrual cycle affects how well it works in triple-negative breast cancer. Women with regular periods who are about to start chemo before surgery may be eligible.
This study follows women who have had cancer or a blood disorder and chose to preserve their fertility before treatment. Researchers want to see how well these preservation methods work over time.
This study looks at how well the ovaries work in women who had childhood cancer. Researchers want to know if cancer treatments affected fertility.
This trial tests whether acupuncture can help bring back periods in young women who lost them due to chemotherapy. It may also help with menopause symptoms for those on hormone-suppressing treatments.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Hear when a new Chemotherapy-Induced Amenorrhea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.